Procedure: Innovative Drug MA (Novel NDA)
Country: Global Procedure
Version #: 12/07/2023
Author: Daria Kostiuchenko
Editor: Daria Kostiuchenko

ID: GP-PhR-NDA-SR
Category: Pharmaceuticals
Validity: Lifetime/5 years/country-specific
Certified by: Vlad Reznikov
Copyright: Pattern of USA Inc.

SUMMARY

The New Market Authorization (MA) for Innovative Drug Registration, known as Novel NDA, is a regulatory process facilitating the approval and introduction of new and innovative drugs to the market. This process involves a comprehensive assessment of the drug’s safety, efficacy, and quality by the NRA. The Novel NDA registration specifically targets drugs lacking prior approval or MA in a particular country. 
The NDA is an extensive document providing data on animal and human studies, the drug’s pharmacology, toxicology, dosage, and details about the drug’s manufacturing process. It adopts the eCTD format as an interface and international specification for the pharmaceutical industry to transfer regulatory information to agencies. Additional specifications may be applicable at national and continental levels. In the U.S., the FDA supplements standard eCTD submissions with specifications such as PDF, transmission, file format, and supportive file requirements. Similarly, the EU EMA outlines the EU Module 1 specification and other quality assurance (QA) documents for eCTD submissions. It is important to note that Regional Module 1 varies by region and country, while Common Modules 2–5 remain consistent across countries.

Gp Innovative Drug New Ma (novel Nda) Simplified Regulations Card Gantt Chart Page 0001

Must-Have Requirements, Recognized Standards, and Certifications:

    • cGMP/Establishment Registration
    • NTE as NCE, NME, NAS, or NBE pertinence
    • Rx or OTC drug designation
    • Drug samples
    • MAs in other countries & marketing history
    • Pharmacologic class EPC/ATC definition
    • Labeling and Medication Guide if applicable
    • Compliance with eCTD incl. modules:
    • 1. Administrative and prescribing information.                                2. Common technical document summaries.                                  3. Quality.                                                                                                4. Nonclinical study reports.                                                                5. Clinical study reports.                                                                       

  • CMC, nonclinical PhC/TX, human PhK/BA/BE, Microbio(anti-inf. drugs) & Clin.Trials Summaries
  • List of applicable standards and certification
  • Claimed exclusivity or Licensing agreements if so
  • Authorized Representative under POA see GP-PhR-AR-SR card
  • Patent or Regulatory Intelligence Report see GP-PhR-RI-SR card
  • Identifying Simplified NDA (e.g. US 505) see GP-PhR-GAP-SR card
  • Compliance with country-specific regulations
  • QMS/QA/PV. Addit. information could be required 

Nice-to-have

  • cGCP
  • cGLP    
  • cISO 9001
  • cISO 27001
  • cISO 14001
  • cISO 45001

Typical Gaps and Deficiencies: Insufficient data, incomplete documentation, non-compliance with regulatory guidelines

Implementation Period: After Approval

Deliverables: MA, methods of state controls, NRA post-marketing guidelines and requirements

PHASE

TASK

TASK

START

DURATION

 

Fee

 

KPI

NUMBER

TITLE

OWNER

W/M/Q/Y

in weeks

3rd Party 

Service 

State

 

0

In-house Pre-Submission Activity

       

  0.1

NDA signing or validation

Executor

week 1

1

    

  0.2

Contract Closing

MAH

week 1

1

    

  0.3

POA issuance and shipping

MAH

week 1

1

    

  0.4

Invoice is sent to MAH and paid

Executor

week 1

1

    

  0.5

Legal Document processing

Executor

week 2

1

    

  0.6

Legal Document Translations, Notary, and Apostilles 

3rd party

week 2

2

    

  0.7

SOW is approved by MAH

Executor

week 4

1

   

SOW

I

Submission

       

  I.1

Providing documents and registration file

MAH

week 5

1

    

  I.2

Ensure alignment with local regulatory guidelines

Executor

week 6

2

    

  I.3

Translations and document processing

3rd party

week 8

2

    

  I.4

Filling out the application form

Executor

week 10

1

    

  I.5

Approval of the application form

MAH

week 10

1

    

  I.6

Submission of the New Drug Application and Reg. File

Executor

week 11

1

   

Application

  I.7

    NRA payment

MAH

week 11

1

   

Confirmation

II

NRA Evaluation

       

  II.1

Application review

NRA

week 12

2

    

  II.2

Registration file review

NRA

week 13

4

    

  II.3

Determining of Specific lab testing requirements

NRA

week 17

1

    

  II.4

State-approved lab contracting

Executor

week 18

2

    

  II.5

Samples and Ref. Standards permit obtaining 

Executor

week 20

1

    

  II.6

Samples and Ref. Standards shipping

MAH

week 21

2

    

  II.7

Samples and Ref. Standards custom clearance

Executor

week 23

1

    

  II.8

Optional clinical evaluation (in some countries)

Executor

week 24

8

    

  II.9

Verification of medication guidelines and drug labeling

NRA

week 32

2

    

  II.10

Verification of DHCP Letter and Communication Plan

NRA

week 32

2

    

  II.11

Approval or Query

NRA

week 33

1

   

Approval or Q&A

III

Q&A

       

  III.1

Analysis and addressing Qs to MAH

Executor

Mnth 8

1

    

  III.2

Answering with relevant documents

MAH

Mnth 8

1

    

  III.3

Official Response Evaluation

NRA

Mnth 8

1

    

  III.4

Approval or Query

NRA

Mnth 8

1

   

Approval or Q&A

IV

Approval

       

  IV.1

Market Authorization Approval

NRA

Mnth 9

1

    

  IV.2

Reporting to MAH, compliance check

Executor

Mnth 10

1

   

Approval

  IV.3

Listing in the state register

Executor

Mnth 10

1

   

Listing

F

Final Phase In-house Post-Authorization Activity

       

  F.1

Service Acceptance Certificate signing

MAH

Mnth 10

1

    

  F.2

Final Invoice

Executor

Mnth 10

1

    

  F.3

Final Payment

MAH

Mnth 10

1

    

  F.4

Contract Termination

Executor

Mnth 10

1

    

  F.5

Archiving and limiting access

Executor

Mnth 10

1

   

Archiving

 

Feel free to submit a Request for Proposal (RFP) for a specific country or territory to info@patternofusa.com